MannKind (MNKD) PT Raised to $11 at H.C. Wainwright

H.C. Wainwright analyst Brandon Folkes raised the price target on MannKind (NASDAQ: MNKD) to $11.00 (from $9.00) while maintaining a Buy rating.

The analyst commented: "On 9/2/2025, UTHR announced that Tyvaso (treprostinil) Inhalation Solution met its primary efficacy endpoint of demonstrating improvement in absolute forced vital capacity (FVC) relative to placebo. Tyvaso demonstrated superiority over placebo for the change in absolute FVC by 95.6 mL (Hodges-Lehmann estimate, p <0.0001) from baseline to week 52 in patients with IPF. Benefits of Tyvaso were observed across all subgroups, such as use of background therapy (nintedanib, pirfenidone, or no background therapy), smoking status, and supplemental oxygen use. Statistically significant improvements relative to placebo were also observed in most secondary endpoints, including time to first clinical worsening event, as well as changes from baseline to week 52 in percent predicted FVC, King’s Brief Interstitial Lung Disease quality of life questionnaire (K-BILD), and diffusion capacity of lungs for carbon monoxide (DLCO). United Therapeutics plans to use data from both the completed TETON-2 study and the ongoing TETON-1 study (NCT04708782) to support a supplemental New Drug Application to the FDA seeking to add IPF as an approved indication for nebulized Tyvaso."

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Jefferies on Five Below (FIVE): 'Our latest channel checks reinforce our view that FIVE's momentum extends well beyond viral Squish trends'
• Freedom Broker Upgrades Lifeway Foods (LWAY) to Buy